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A B S T R A C T
Purpose
Lymphoma patients commonly experience declines in physical functioning and quality of life (QoL)
that may be reversed with exercise training.
Patients and Methods
We conducted a randomized controlled trial in Edmonton, Alberta, Canada, between 2005 and
2008 that stratified 122 lymphoma patients by major disease type and current treatment status
and randomly assigned them to usual care (UC; n  62) or 12 weeks of supervised aerobic
exercise training (AET; n  60). Our primary end point was patient-rated physical functioning
assessed by the Trial Outcome Index-Anemia. Secondary end points were overall QoL, psycho-
social functioning, cardiovascular fitness, and body composition.
Results
Follow-up assessment for our primary end point was 96% (117 of 122) at postintervention and
90% (110 of 122) at 6-month follow-up. Median adherence to the supervised exercise program
was 92%. At postintervention, AET was superior to UC for patient-rated physical functioning
(mean group difference, 9.0; 95% CI, 2.0 to 16.0; P  .012), overall QoL (P  .021), fatigue
(P  .013), happiness (P  .004), depression (P  .005), general health (P  .001), cardiovascular
fitness (P .001), and lean body mass (P .008). Change in peak cardiovascular fitness mediated
the change in patient-rated physical functioning. AET did not interfere with chemotherapy
completion rate or treatment response. At 6-month follow-up, AET was still borderline or
significantly superior to UC for overall QoL (P  .054), happiness (P  .034), and depression
(P  .009) without an increased risk of disease recurrence/progression.
Conclusion
AET significantly improved important patient-rated outcomes and objective physical functioning in
lymphoma patients without interfering with medical treatments or response. Exercise training to
improve cardiovascular fitness should be considered in the management of lymphoma patients.
J Clin Oncol 27:4605-4612. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Lymphoma is the fifth most common cancer in the
United States and Canada with 75,000 Americans
and 8,000 Canadians diagnosed in 2008.1,2 Non-
Hodgkin’s lymphoma (NHL) comprises 89% of
lymphomas with the remainder being Hodgkin’s
lymphoma (HL). Five-year relative survival is 63%
for NHL and 85% for HL. Lymphoma patients are
often treated multiple times with chemotherapy,
radiation therapy, and/or biologic therapy inter-
spersed with active surveillance. The disease and its
repeated treatments can produce adverse effects in-
cluding physical deconditioning, body composition
changes, fatigue, depression, and reduced quality of
life (QoL).3-6 Few interventions have been shown to
improve these outcomes.
Exercise training improves health outcomes in
breast7 and prostate8 cancer patients but no ran-
domized controlled trials (RCTs) have focused on
lymphoma patients.9 Generalizing from breast
and prostate to lymphoma may be unwise given
differences in demographics, disease pathology,
prognosis, treatments, and symptoms/adverse ef-
fects.Here, we report results from theHealthy Exer-
cise for Lymphoma Patients (HELP) trial which, to
the best of our knowledge, is the first exercise RCT
in lymphoma patients. We hypothesized that aer-
obic exercise training (AET) would be superior to
usual care (UC) for patient-ratedoutcomes (PROs),
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cardiovascular fitness, and body composition. We also expected car-
diovascular fitness improvements to mediate improvements in the
PROs.We includedpatients receivingchemotherapyoroff treatments
to explore potential differences in response. Chemotherapy comple-
tion rate, treatment response, and disease recurrence weremonitored
for safety purposes and considered exploratory end points.
PATIENTS AND METHODS
The studywas a single-center, two-armedRCT. Ethical approvalwas obtained
from the Alberta Cancer Board and the University of Alberta, and written
informed consent was obtained from participants.
Setting and Participants
Participants were recruited from the Cross Cancer Institute in Edmon-
ton, AB, Canada. Eligibility criteria included English speaking, 18 years old,
histologically confirmed HL or NHL, and receiving chemotherapy or no
treatments. Patients receiving chemotherapy may have started treatment be-
fore enrollment but needed to have at least 8 weeks of planned treatment
remaining. Patients not receiving treatments had to have no planned treat-
ments during the intervention period. Patients were excluded if they had
uncontrolled hypertension, cardiac illness, lived more than 80 km from the
facility, or otherwise were not approved by their oncologist. Patients were not
excluded on the basis of baseline exercise in order to mimic clinical prac-
tice. If randomly assigned to AET, participants were asked to complete the
program in addition to their baseline exercise. Eligible patients were identi-
fied by seven treating oncologists and a mailed invitation using the Alberta
Cancer Registry on the basis of the same eligibility criteria. Patients recruited
through the mail obtained approval from their treating oncologist. Our goal
was to recruit approximately 50% of patients receiving chemotherapy and
50% off treatment.
Randomization and Blinding
After completing baseline tests, participants were stratified by major
disease type (HL, indolent NHL, aggressive NHL) and current treatment
status (chemotherapy, off treatments) andwere randomly assigned to AET
or UC by using a computer-generated program. The allocation sequence
was generated independently and concealed in opaque envelopes from the
study coordinator who assigned participants to groups. Outcomes assessors
werenotalwaysblinded togroupassignmentbutwere trained instandardizing
testing procedures.
Patients receiving chemotherapy
assessed for eligibility in the clinic
(n = 552)
Patients off treatment assessed
for eligibility in the clinic
(n = 430)
Patients off treatment
contacted by mail
(n = 324)
Patients stratified by disease type
(HL v NHL aggressive v NHL indolent) and
treatment status (receiving chemotherapy 
v no treatment) randomly assigned
(n = 122)
Patients included in all intention
to treat analyses
(n = 62; 100%)
Patients included in all intention
to treat analyses
(n = 60; 100%)
Post-test assessment
  PROs (n = 60; 97%)
  Aerobic fitness (n = 56; 90%)
  Body composition (n = 58; 94%)
PROs, 6-month follow-up (n = 55; 89%)
Post-test assessment
  PROs (n = 57; 95%)
  Aerobic fitness (n = 52; 87%)
  Body composition (n = 53; 88%)
PROs, 6-month follow-up (n = 55; 92%)
PROs*
  No response (n = 2)
Fitness
  Too sick (n = 2)
  No response (n = 2)
  Recurrence (n = 2)
DXA
  Recurrence (n = 2)
  No response (n = 1)
  Too sick (n = 1)
PROs†
  No response (n = 5)
  Died (n = 1)
  No interest (n = 1)
PROs*
  No response (n = 2)
  Too sick (n = 1)
Fitness
  Too sick (n = 4)
  No response (n = 2)
  Schedule (n = 2)
DXA
  Schedule (n = 4)
  No response (n = 2)
  Too sick (n = 1)
PROs†
  No response (n = 3)
  Died (n = 1)
  Moved (n = 1)
Patients excluded (n = 499; 90%)
  Ineligible (n = 340)
  Declined to participate (n = 159)
Of eligible randomly assigned (n = 53; 25%)
Patients excluded (n = 383; 89%)
  Ineligible (n = 251)
  Declined to participate (n = 132)
Of eligible randomly assigned (n = 47; 26%)
Patients excluded (n = 302; 93%)
  Did not respond (n = 212)
  Responded but ineligible (n = 29)
  Responded but declined to participate (n = 61)
Of eligible responders randomly
  assigned (n = 22; 27%)
Patients assigned to supervised
  aerobic exercise (n = 60)
  Attended ≥ 66% of sessions (n = 45; 75%)
  Attended ≥ 80% of sessions (n = 39; 65%)
  Attended 100% of sessions (n = 21; 35%)
Patients assigned to usual care (n = 62)
  Reported no regular vigorous exercise
    during intervention (n = 49; 79%)
  Reported regular vigorous exercise
    during intervention (n = 13; 21%)
  Mean change in vigorous exercise from
    baseline: -4 minutes
Fig 1. CONSORT diagram showing flow of participants through the trial. (*) Postintervention; (†) 6-month follow-up. HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s
lymphoma; PRO, patient-rated outcome; DXA, dual energy x-ray absorptiometry.
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Intervention
Participants randomly assigned to AET received an exercise program
designed to maximize cardiovascular fitness on the basis of research sug-
gesting that cardiovascular fitness improvements may optimize PROs.10
Sessions were supervised by exercise physiologists and completed on an up-
right or recumbent cycle ergometer (Life Fitness, Schiller Park, IL) three times
perweek for12weeks. Intensitybeganat 60%of thepeakpoweroutput,which
corresponded with baseline peak oxygen consumption (VO2peak), and was
increasedby5%eachweek to75%by the fourthweek.Durationbeganat 15 to
20minutes for thefirst 4weeks and increasedby5minutesperweek to40 to45
minutes in the ninth week. On the basis of research suggesting that interval
training can maximize cardiovascular fitness improvements in cancer pa-
tients,11 we instituted one session per week of interval training above the
ventilatory threshold inweek 7 and one session of VO2peak interval training in
week 9. To maximize adherence, we incorporated behavioral support tech-
niques based on the theory of planned behavior,12 including an attractive
facility, flexible hours, scheduled exercise sessions, telephone follow-up after
missed sessions, positive reinforcement from staff, variation in exercise, and
paid parking. UC participants were asked not to increase exercise above
baseline and were offered 4 weeks supervised exercise after postinterven-
tion assessments.
Assessment of Primary and Secondary End Points
PROs were assessed at baseline (before random assignment), postinter-
vention, and at 6-month follow-up. The primary time point of interest was
postintervention, and the primary end point was patient-rated physical func-
tioning assessed by the Trial Outcome Index-Anemia (TOI-An) from the
well-validated Functional Assessment of Cancer Therapy-Anemia (FACT-
An) scale.13We selected theTOI-Anas theprimary endpoint because exercise
maybeparticularly beneficial for thephysical functioning aspects ofQoL.7We
also analyzed the total FACT-An and the Fatigue subscale. Happiness was
assessed by the Happiness scale14; depression by the short-form (SF) Center
for Epidemiological Studies-Depression scale15; anxiety by the SF Spielberger
State Anxiety Inventory16; lymphoma symptoms by the lymphoma subscale
from theFACT17; and general health by the single item from the SF1218 asking
respondents to rate their health from poor to excellent.
Objective fitness outcomes were assessed at baseline and postinterven-
tion. Cardiovascular fitness was assessed by a maximal graded exercise test
administeredbyanexercisephysiologistwithphysician-supervisedECGmon-
itoring (CardioStress ECG; Nassif Associates, Central Square, NY). The pro-
tocol for this test has been published,19 and it follows American Thoracic
Society guidelines.20 Metabolic data were averaged over 15 seconds, with the
highest 15-second VO2 value recorded as VO2peak and the corresponding
power output recorded as peak power output. Ventilatory threshold was
determined by using the ventilatory equivalent method.20
Body weight and standing height were assessed using a balance beam
scale (Health ometer, Shelton, CT). Dual x-ray absorptiometry assessed body
composition (General Electric Healthcare, Piscataway, NJ). For participants
receiving chemotherapy, treatment completion rate was assessed as the num-
berof cycles completeddividedby theminimal andmaximalnumberof cycles
planned. Treatment response was recorded as progressive, stable, partial re-
sponse, or complete response (unconfirmed and confirmed). For all partici-
pants, progression or recurrence at 6-month follow-up was abstracted from
medical records.
Assessment of Covariates, Adherence, and Adverse Events
Demographic and behavioral datawere collected by self-report.Med-
ical data were abstracted from medical records. Exercise trainers moni-
tored adherence and adverse events. Nonprotocol exercise was assessed
using self-report.21
Data Analyses
Sixty participants per group provided a 0.80 power to detect a change
score difference of 10 (standard deviation 18) on theTOI-Anwith 10% loss
to follow-up and two-tailed alpha less than .05. Linear mixed-model analysis
modeled each outcome measure at two time points (either baseline and
postintervention or baseline and 6-month follow-up) and compared the dif-
ferences between groups in changes over time using intention-to-treat analy-
ses and all available data.22 Our primary analysis was unadjusted, but we also
conducted analyses adjusted for baseline value of the outcome, disease type,
stage, treatment status, age, sex, and baseline exercise (defined as  150
minutes of moderate exercise per week). We also used mixed-model analysis
to assess effect modification by our stratification variables (major disease type
and treatment status) in an interaction test.22 Patient-rated general healthwas
categorized as worsened (declined at least one category), stable (no change in
category), or improved (increased at least one category) and analyzed using2
analysis for participants with complete data. Chemotherapy completion rate,
initial treatment response, and recurrence/progression during follow-upwere
also analyzed using 2 analysis and included all participants because no treat-
mentdataweremissing.Multiple regressionwasused to test themediatingrole
of cardiovascular fitness for postintervention PRO change scores in partici-
pants with complete data.23 This approach requires that the outcome of
interest (the PRO) be regressed on the proposed mediator (fitness) and the
intervention (group assignment coded as 0UCand 1AET).Mediation is
present when the proposedmediatormaintains a significant relationshipwith
the outcome whereas group assignment does not.
RESULTS
Recruitment occurred between May 2005 and May 2008. We re-
cruited9%(122of 1,306)of screenedpatients and26%(122of 474)of
eligible patients (Fig 1). Reasons for ineligibilitywere livingmore than
80 km from the facility (n 268), treatment adverse effects (n 90),
serious conditions (n 86), and frailty (n 82). Reasons for refusal
were too busy (n 83), no reason (n 70), not interested (n 40),
transportation issues (n 40), and currently exercising (n 30).We
obtained postintervention data on the PROs from 117 of 122 (96%)
participants and 6-month data from 110 of 122 (90%) participants.
Groups were balanced on baseline covariates (Table 1). The AET
group attended a mean of 77.8% (28.0 of 36) and a median of 91.7%
(33.0 of 36) of the supervised sessions. Duration and intensity were
met during 99.0% (27.8 of 28.0) and 90.7% (25.4 of 28.0) of the
supervised sessions, respectively. Fewer than 25% reported regular
exercise outside of the trial in either group (P .71). Twenty-six of 62
(42%) UC participants attended supervised exercise after postinter-
vention assessments.
Changes in PROs at Postintervention
At postintervention, AET was superior to UC for patient-rated
physical functioning (P  .012), overall QoL (P  .021), fatigue
(P .013), happiness (P .004), and depression (P .005; Table 2).
Results remained significant after adjustment (Table 2). General
health was improved in AET compared with UC (P  .001; Fig 2).
Neither disease type (P for interaction  0.46; Fig 3A) nor current
treatment status (P for interaction  0.70; Fig 4A) moderated the
effectsofAETontheTOI-An(oranyotherPROs;datanotpresented).
Changes in Objective Fitness Outcomes
at Postintervention
At postintervention, AETwas superior toUCon all indicators of
cardiovascularfitness (Pvalues .001) and leanbodymass (P .008)
and forpercentbody fat after adjustments (P .050;Table 3).Neither
disease type (P for interaction 0.21; Fig 3B) nor current treatment
Exercise in Lymphoma Patients
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Table 1. Baseline Characteristics of Participants, Overall and by Group Assignment
Characteristic
Overall
(N  122)
Usual Care
(n  62)
Aerobic Exercise
Training
(n  60)
PNo. % No. % No. %
Demographic profile
Age, years .809
Mean 53.2 53.5 52.8
Range 18-80 18-80 18-77
18-39 22 18.0 12 19.4 10 16.7
40-59 51 41.8 25 40.3 26 43.3
 60 49 40.2 25 40.3 24 40.0
Male 72 59.0 35 56.5 37 61.7 .558
Married 94 77.0 46 74.2 48 80.0 .446
Completed university 63 51.6 32 51.6 31 51.7 .995
Income  $60,000/year 73 62.9 39 62.9 34 63.0 .995
Employed 54 44.3 32 51.6 22 36.7 .097
Cancer profile
Major cancer type .978
NHL indolent 52 42.6 27 43.5 25 41.7
NHL aggressive 48 39.3 24 38.7 24 40.0
Hodgkin’s lymphoma 22 18.0 11 17.7 11 18.3
Most common cancer subtypes .472
Diffuse large B cell 42 34.4 21 33.9 21 35.0
Follicular 29 23.8 15 24.2 14 23.3
Nodular sclerosing 19 15.6 10 16.1 9 15.0
Chronic lymphocytic leukemia 14 11.5 10 16.1 4 6.7
Disease stage .653
I 18 14.8 7 11.3 11 18.3
II 23 18.9 15 24.2 8 13.3
III 17 13.9 8 12.9 9 15.0
IV 28 23.0 13 21.0 15 25.0
No evidence of disease 34 27.9 18 29.0 16 26.7
Unclear 2 1.6 1 1.6 1 1.7
Previous treatments
Chemotherapy 54 44.3 28 45.2 26 43.3 .839
Radiation therapy 28 23.0 15 24.2 13 21.7 .740
Current treatment status .599
Chemotherapy 54 44.3 26 41.9 28 46.7
Off treatment 68 55.7 36 58.1 32 53.3
Time since diagnosis, months .234
Mean 29.2 33.0 25.3
SD 35.6 39.0 31.5
Health profile
Most common comorbidities
Arthritis 38 31.1 14 22.6 24 40.0 .038
Hypercholestremia 36 29.5 18 29.0 18 30.0 .907
Hypertension 35 28.7 21 33.9 14 23.3 .198
Weight, kg .243
Mean 80.1 78.5 81.8
SD 16.0 17.1 14.8
BMI, kg/m2 .470
Mean 27.1 26.7 27.4
SD 4.9 5.4 4.5
Healthy weight 42 34.4 25 40.3 17 28.3
Overweight 47 38.5 20 32.3 27 45.0
Obese 33 27.0 17 27.4 16 26.7
Current smoker 13 10.7 9 14.5 4 6.7 .160
Baseline exerciser 35 28.7 23 37.1 12 20.0 .037
Abbreviations: NHL, non-Hodgkin’s lymphoma; SD, standard deviation; BMI, body mass index.
n  116.
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status (P for interaction 0.40; Fig 4B)moderated the effects of AET
on VO2peak (or any other fitness outcome; data not presented).
Chemotherapy Completion Rate and
Treatment Response
For participants receiving chemotherapy (n  54), the AET
group (n 28) completed 103%of its plannedminimumand94%of
its plannedmaximum cycles compared with 99% (P .45) and 89%
(P .20) for UC (n 26), respectively. A complete response (con-
firmed or unconfirmed)was achieved by 46.4% (13 of 28) in the AET
group and 30.8% (8 of 26) in the UC group (P .24).
Mediation of PROs by Objective Fitness Outcomes
Change in VO2peak mediated the effect of the intervention on
change in theTOI-An (VO2peak: .29;P .026; group assignment:
 .02; P .90). Borderline significant mediation was observed for
fatigue (VO2peak:   .23; P  .073; group assignment:   .05;
P .71) and the FACT-An (VO2peak: .21; P .10; group assign-
ment: .05;P .69).VO2peak didnotmediate the effects ofAETon
happiness (VO2peak:   .03; P  .83; group assignment:   .28;
P .032) or depression (VO2peak: .14; P .29; group assign-
ment: .17; P .19). Other objective fitness indicators did not
mediate (data not presented).
Six-Month Follow-Up
At 6-month follow-up, changes in patient-rated physical func-
tioning favored theAETgroupbutdidnot reachstatistical significance
(mean difference,5.5; 95%CI,1.5 to 12.4; P .121). There was a
borderline significant change in favor of AET for overall QoL (mean
difference,7.6; 95% CI,0.1 to 15.4; P .054), and a significant
difference for happiness (mean difference,8.9; 95% CI, 0.7 to 17.1;
P  .034) and depression (mean difference, 2.5; 95% CI, 0.6 to
4.4;P .009). Recurrence/progression during the 6-month follow-up
was noted in 6.7% (4 of 60) of the AET group and 11.3% (7 of 62) of
theUCgroup(P .37).Regular exercisewas reportedby63.6%(35of
55) in theAETgroup and 40.0%(22of 55) in theUCgroup (P .017).
Adverse Events
No serious events but three adverse events (back, hip, and knee
pain) were related to exercise. The participant with knee pain with-
drew fromexercisewhereas the twoother participants continuedwith
a modified exercise program.
Table 2. Effects of Aerobic Exercise Training on Patient-Rated Outcomes at Postintervention in Lymphoma Patients
Outcome
Baseline Post-Test Mean Change
Unadjusted Group Difference
in Mean Change
Adjusted Group Difference in
Mean Change
Mean SD Mean SD Mean 95% CI Mean 95% CI P Mean 95% CI P
TOI-An, 0-136
UC 105.1 21.1 105.4 22.0 0.4 4.5 to 5.3 9.0 2.0 to 16.0 .012 7.2 1.3 to 13.1 .017
AET 100.1 21.9 109.3 18.7 9.4 4.4 to 14.4
FACT-An, 0-188
UC 147.1 24.3 148.1 25.7  1.1 4.5 to 6.7 9.5 1.5 to 17.5 .021 7.2 0.4 to 14.1 .039
AET 140.7 26.8 151.4 21.7 10.6 4.9 to 16.3
Fatigue, 0-52
UC 38.0 10.7 38.0 11.1 0.1 2.7 to 2.4 4.6 1.0 to 8.3 .013 4.0 0.9 to 7.0 .012
AET 36.1 10.8 40.5 9.4 4.5 1.9 to 7.1
Happiness, 0-100
UC 66.9 19.2 67.2 18.5  0.7 4.0 to 5.5 10.0 3.2 to 16.7 .004 6.8 1.4 to 12.3 .015
AET 59.6 22.4 70.9 16.4 10.7 5.9 to 15.5
Depression, 0-30
UC 6.0 4.5 6.1 5.0 0.2 1.0 to 1.3 2.4 4.0 to 0.7 .005 1.6 3.0 to 0.1 .031
AET 7.7 5.7 5.4 4.5 2.2 3.4 to 1.0
Anxiety, 10-40
UC 16.9 5.4 16.2 5.2 0.6 2.0 to 0.8 1.0 3.0 to 1.0 .323 0.4 2.1 to 1.3 .642
AET 18.4 6.6 16.5 5.2 1.6 3.0 to 0.2
Lymphoma symptoms, 0-60
UC 47.7 8.7 49.3 8.2 1.5 0.1 to 3.1 1.2 1.1 to 3.5 .306 1.3 0.7 to 3.2 .199
AET 47.4 8.7 50.3 7.2 2.7 1.1 to 4.4
NOTE. Mean and SD at post-test are based on available data. Mean change is estimated on the basis of mixed model analysis. Adjusted group difference
in mean change was adjusted for baseline value of the outcome, major cancer type, disease stage, current treatment status, age, sex, and baseline exercise.
Possible range of scale shown next to patient-rated outcomes in left column.
Abbreviations: SD, standard deviation; TOI-An, Trial Outcome Index-Anemia; UC, usual care; AET, aerobic exercise training; FACT-An, Functional Assessment of
Cancer Therapy-Anemia.
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Fig 2. Category change in patient-rated general health by group assignment.
UC, usual care; AET, aerobic exercise training.
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DISCUSSION
Consistent with our hypotheses, AET significantly improved patient-
rated physical functioning, overall QoL, fatigue, general health, hap-
piness, depression, cardiovascular fitness, and lean body mass in
lymphoma patients receiving chemotherapy or off treatments.
Change in VO2peakmediated the effect of the intervention on patient-
rated physical functioning but not psychosocial functioning. Major
disease type and current treatment status did not alter the results. For
participants receivingchemotherapy,AETdidnot interferewith treat-
ment completion or response. Some beneficial effects were still
present at the 6-month follow-up despite substantial exercise cross-
over during follow-up.
The effects of AETon the PROs appearmeaningful. The effect of
9.0 points on the TOI-An exceeds the 6.0 minimal important differ-
ence for this scale.13 The effects on the FACT-An and fatigue scales of
9.6 and 4.6 also exceed the minimal important differences for these
scales of 7.0 and 3.0, respectively.13 Few published exercise studies in
lymphomapatients are available for comparison.9 A recent systematic
review of 10 intervention studies in adult hematologic cancer patients
treated with stem cell transplantation concluded that methodologic
quality is poor to modest, and effectiveness has not been demon-
strated. In a single-arm trial of nine HL patients with severe fatigue,
Oldervoll et al24 reported improvements in fatigue, physical function-
ing, and cardiovascular fitness after 20 weeks of unsupervised aerobic
exercise. In a cross-sectional survey of 438NHL survivors, Vallance et
al25 reported favorable associations between regular exercise and
physical functioning, fatigue, and overall QoL.
Exercise RCTs in other cancer patient populations are available
for comparison. In a meta-analysis of 14 RCTs involving 717 breast
cancer patients, McNeely et al7 reported a benefit of 6.6 points on the
FACT-Breast scale and a standardized effect size (d) of 0.46 on fatigue.
In a meta-analysis of 20 RCTs involving 1,662mixed cancer patients,
Cramp and Daniel26 reported a small but significant overall effect of
exercise on fatigue (d 0.23) that was slightly larger for breast cancer
patients (d 0.34). Our improvement in fatigue is noteworthy, given
the difficulty of managing this symptom in cancer patients.27
Our exercise intervention also improved cardiovascular fitness
by more than 20%. This improvement is larger than that typically
reported inothercancerpatientpopulations7,26 andmayhaveresulted
fromour higher intensity training program supplementedwith inter-
val training. Improving cardiovascular fitness in lymphoma patients
may have implications for disease outcomes and survival based on
research in other populations,28,29 although such associations have
notbeenestablished in lymphomapatientsor anyother cancerpatient
populations. Improvements in lean body mass may also have impli-
cations for improvedphysical functioning, disease risk, and survival.30
Improvement inVO2peakmediated the effects ofAETonpatient-
rated physical functioning and was borderline significant for fatigue.
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This finding is consistentwith a previous trial in postadjuvant therapy
breast cancer survivors10 and with other trials that have reported
associations between changes in objective fitness and PROs.31,32
Interestingly, other fitness indicators did not mediate the effects of
our intervention, suggesting that maximizing improvements in
VO2peak may be the best strategy for improving physical and func-
tional aspects of QoL in lymphoma patients. Finally, consistent with
our previous trial,10 improvements in psychosocial outcomes (happi-
ness and depression) were not mediated by fitness parameters, sug-
gesting that other aspects of the intervention may explain these
improved outcomes (eg, increased social interaction, distraction
from cancer/treatments).
Our results were not modified by major disease type or current
treatment status although we acknowledge that our trial was not
powered to detect interactions. In terms of major disease type, it
appears that the effects on theTOI-AnandVO2peakwere larger forHL
patients, butwehadonly22HLpatients in the trial, and thisdifference
could easily be due to chance. In termsof current treatment status, the
magnitude of the effects on the TOI-An and VO2peak were virtually
identical, suggesting that even larger trials may not yield meaningful
interaction effects based on treatment status. This finding is at odds
with results from recent meta-analyses suggesting larger exercise ef-
fects in the postadjuvant setting compared with the adjuvant set-
ting.7,26 Importantly, thesemeta-analyses are based almost entirely on
breast cancer trials and may not generalize to other cancer patient
populations. Consistent with expectations, our trial showed that the
benefits of exercise during chemotherapy consisted of both preven-
tion of decline and actual gains in functioning whereas the off-
treatment benefits consisted entirely of gains.
Importantly, our exercise trainingprogramdidnot interferewith
lymphoma patients’ ability or willingness to complete chemotherapy
or their clinical response to treatment.We acknowledge that our trial
was not powered to answer these questions; however, the differ-
ences favored the exercise group. Few exercise RCTs have tracked
treatment factors. We recently reported that breast cancer patients
engaged in resistance training completed a higher relative dose inten-
sity of chemotherapy compared with UC,31 but the finding was not
expected and needs replication. At a minimum, it appears that vigor-
ous intensity exercise during chemotherapy does not jeopardize treat-
ment outcomes.
Our trial’s strengths include being the first exercise RCT to focus
on lymphoma patients, an adequate overall sample size, supervised
exercise, excellent adherence, a comprehensive assessment of impor-
tant outcomes with validated measures, intention-to-treat analysis,
minimal loss to follow-up, and statistically and clinically meaningful
effects on outcomes. Limitations include the heterogeneity of this
patient population, our limited power to detect subgroup effects, the
short 12-week exercise intervention, the 25% recruitment rate from a
single center, the substantial exercise crossover during follow-up that
likely attenuated group differences at 6months, and the 15 postint-
ervention group comparisons that would likely result in one false
discovery if all comparisons were null. In terms of dissemination, this
intervention could be implemented at other cancer centers and
community-based fitness centers with appropriate facilities and
Table 3. Effects of Aerobic Exercise Training on Objective Fitness Outcomes at Postintervention in Lymphoma Patients
Outcomes
Baseline Post-Test Mean Change
Unadjusted Group Differences
in Mean Change
Adjusted Group Differences in
Mean Change
Mean SD Mean SD Mean 95% CI Mean 95% CI P Mean 95% CI P
VO2peak, L/min
UC 1.98 0.71 1.96 0.69 0.03 0.09 to 0.03 0.43 0.34 to 0.52  .001 0.43 0.34 to 0.52  .001
AET 2.02 0.66 2.38 0.81 0.40 0.34 to 0.47
VO2peak, mL/kg/min
UC 25.4 9.2 25.2 9.1 0.6 1.5 to 0.3 5.2 4.0 to 6.5  .001 5.2 4.0 to 6.4  .001
AET 24.7 7.2 29.4 8.6 4.6 3.7 to 5.5
Peak power output, watts
UC 146 57 148 56 2 4 to 8 29 20 to 37  .001 28 20 to 37  .001
AET 148 56 176 69 31 25 to 37
Ventilatory threshold, L/min
UC 1.09 0.37 1.04 0.35 0.03 0.09 to 0.02 0.33 0.26 to 0.41  .001 0.33 0.26 to 0.41  .001
AET 1.07 0.35 1.35 0.50 0.32 0.16 to 0.48
Body weight, kg
UC 78.5 17.1 78.7 16.0 0.5 0.3 to 1.3 0.6 0.5 to 1.8 .276 0.5 0.6 to 1.6 .381
AET 81.8 14.8 81.5 16.0 1.2 0.3 to 2.0
Lean mass, kg
UC 49.9 10.0 49.8 9.9 0.1 0.3 to 0.5 0.8 0.2 to 1.4 .008 0.8 0.2 to 1.4 .010
AET 52.4 10.9 52.3 11.5 0.9 0.5 to 1.3
Fat mass, kg
UC 25.3 11.8 25.7 11.1 0.6 0.1 to 1.2 0.3 1.2 to 0.7 .589 0.3 1.3 to 0.5 .386
AET 25.8 9.5 26.0 10.1 0.3 0.4 to 1.0
Body fat, %
UC 32.6 10.9 33.2 10.5 0.6 0.1 to 1.2 0.8 0.2 to 1.7 .110 0.9 0.0 to 1.7 .050
AET 32.6 9.9 32.8 10.1 0.2 0.8 to 0.5
NOTE. Mean and SD at post-test are based on available data. Mean change is estimated on the basis of mixed model analysis. Adjusted group difference
in mean change was adjusted for baseline value of the outcome, major cancer type, disease stage, current treatment status, age, sex, and baseline exercise.
Abbreviations: SD, standard deviation; VO2peak, peak oxygen consumption; UC, usual care; AET, aerobic exercise training.
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qualified staff. Given its sophistication in terms of exercise training
principles, it is unclear if such a program could be self-directed by
patients with minimal or no supervision.
In summary, our trial provides the first compelling evidence of
the safety and effectiveness of exercise training in lymphoma patients.
Ourmediationanalyses suggest that improvements inpeakcardiovas-
cularfitnessmay explain the improvements inphysical and functional
aspects of QoL. These data suggest a unique and important role for
exercise in cancer care given that physical and functional aspects of
QoL are often the most compromised in cancer patients and even
long-term survivors.33,34 Exercise training may be considered as a
supportive care intervention for lymphoma patients receiving chem-
otherapy or off treatments. Additional research on the optimal type,
volume, fractionation, and timing of exercise in this understudied
patient population is warranted.
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